Most Read Articles
7 days ago
Obesity has a slight and substantial negative impact on the cognitive functioning of healthy individuals and major depressive disorder patients (MDD), respectively, a new study shows.
10 days ago
Increased serum levels of C-X-C motif chemokine (CXCL)-11, CXCL-9, CXCL-10 and interferon (IFN)-γ are associated with clinical manifestations of adult-onset Still’s disease (AOSD), reports a new study.
2 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
4 days ago
Myopia is associated with depressive symptoms in Chinese adults, a new population-based study shows.

Terlipressin may reverse HRS in patients with systemic inflammatory response syndrome

3 months ago

Terlipressin may produce more favourable outcomes in patients with systemic inflammatory response syndrome (SIRS), improving renal function and reversing hepatorenal syndrome (HRS) compared with albumin plus placebo, a retrospective study suggests.

Researchers reviewed the medical records of 198 patients with HRS type 1 who participated in a trial evaluating the effects of terlipressin (1 mg every 6 hours) vs placebo with concomitant albumin. Two patient groups were identified, including those with two or more criteria for SIRS and those with with less than two criteria for SIRS (controls).

The main endpoints were HRS reversal (serum creatinine level decreasing to ≤1.5 mg/dL), confirmed HRS reversal (two serum creatinine levels ≤1.5 mg/dL; ≥48 hours apart) and survival for 90 days after treatment.

The two patients groups showed similar baseline characteristics, with the exception of SIRS patients having slightly higher white blood cell counts and heart rates and slightly lower serum bicarbonate levels compared with controls.

HRS reversal occurred in 42.9 percent of SIRS patients who received terlipressin (12/28) vs 6.7 percent of those who received placebo (2/30; p=0.0018).

The proportion of patients with confirmed HRS reversal was 32.1 percent in the terlipressin group vs 3.3 percent in the placebo group (p=0.0048). Those who survived for 90 days without a transplant was 46.4 vs 23.3 percent, respectively, (p=0.076).

HRS is characterized by portal hypertension with impaired kidney perfusion by vasoconstrictor endogenous mediators in patients with liver cirrhosis, acute liver failure or alcoholic hepatitis. While the condition may be reversed, HRS poses a life-threatening risk, requiring prompt diagnosis and rapid treatment. [Gastroenterol Res Pract 2015;457613]

Type I HRS is particularly associated with poor prognosis. This subtype develops rapidly, as may be indicated by the doubling of the serum creatinine concentration within 2 weeks. Patients with this HRS type have a mortality of 50 percent after 2 weeks of diagnosis, increasing to 100 percent within months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
7 days ago
Obesity has a slight and substantial negative impact on the cognitive functioning of healthy individuals and major depressive disorder patients (MDD), respectively, a new study shows.
10 days ago
Increased serum levels of C-X-C motif chemokine (CXCL)-11, CXCL-9, CXCL-10 and interferon (IFN)-γ are associated with clinical manifestations of adult-onset Still’s disease (AOSD), reports a new study.
2 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
4 days ago
Myopia is associated with depressive symptoms in Chinese adults, a new population-based study shows.